Redeye retains its positive view on Transtema despite EBITA falling somewhat short of our expectations. In 2021, Transtema highlighted its successful transition, and Q4 gave us positive early signs in potential future growth areas. We leave our Base Case unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Transtema - Stable Ending to an Excellent Year

© Modular Finance, source Nordic Press Releases